Can Activation of NRF2 Be a Strategy against COVID-19? Trends in Pharmacological Sciences, September 2020 steve | 14 July 2020
Effect of SFX-01 on proliferation of human glioblastoma cell lines, BioRxiv, 16 September 2021 steve | 16 September 2021
Final Results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC), Annals of Oncology, 1 October 2019 steve | 1 October 2019
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma, Pharmaceuticals, 26 October 2021 steve | 26 October 2021
SFX-01 in the treatment of rhabdomyosarcoma: Preclinical results in cellular models mel | 27 March 2023
Sulforaphane treatment of autism spectrum disorder (ASD), PNAS, 28 October 2014 mel | 28 October 2014
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer, Nature Oncogene, 20 May 2020 steve | 30 May 2020
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Nature Reviews Drug Discovery, 5 February 2019 steve | 5 February 2019
